Bimatoprost as a Treatment for Graves' Orbitopathy
Launched by JOHNS HOPKINS UNIVERSITY · Oct 13, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called Bimatoprost, which is usually used in eye drops to treat glaucoma. Researchers want to see if Bimatoprost can help reduce eye bulging caused by Graves' disease, a condition that affects the thyroid and can lead to swelling around the eyes. By using Bimatoprost, the goal is to encourage the body to break down some of the fat around the eyes, which may improve the appearance and comfort for patients with Graves' Ophthalmopathy.
To participate in this trial, you need to be between the ages of 65 and 74 and have Graves' Ophthalmopathy with bulging eyes (a condition known as exophthalmos or proptosis). However, you cannot take part if you are currently experiencing active Graves' disease, are pregnant, or are taking steroids. If you join, you will be monitored to see how well the treatment works and if it helps with your symptoms. This trial is currently looking for participants, and it offers a chance to contribute to important research that could improve treatment options for others with similar conditions.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis -
- • Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids
- • -
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Emily Li, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials